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ABSTRACT
A review of animal studies for the efficacy of d-Methionine in reducing threshold shifts and
affecting biochemical changes after exposure to noise
By
Alexandra Petraru
Advisor: Carol A. Silverman, Ph.D., M.P.H.

Noise induced hearing loss (NIHL) is a major public health concern in the United States
and worldwide. Certain individuals such as factory workers and military personnel are at greatest
risk for irreversible sensorineural hearing loss due to the limitations of hearing protection
measures and devices. D-Methionine (d-Met) is an antioxidant otoprotective agent that currently
is in human clinical trials. The purpose of this systematic literature review was to review d-Met’s
efficacy in reducing threshold shifts as well as in producing biochemical and physical changes in
animal studies vis-à-vis the administration paradigm (preloading, rescue and a combined
approach), d-Met dose quantity and the number and schedule of administrations. The results
revealed that d-Met is efficacious across administration paradigms and dosing strategies. A
consensus regarding an optimal dose amount or schedule of administration was not found in the
studies reviewed. Clinical utility for the pre-loading paradigm exists in the opportunity to utilize
d-Met as a prophylactic otoprotective agent. A rescue paradigm similarly provides clinical utility,
offering a way to recover NIHL in cases where noise exposure is unforeseen.
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INTRODUCTION
Noise-induced hearing loss (NIHL) is a significant health issue worldwide, with
considerable financial, social and clinical consequences. It increasingly is impacting young
populations and is the most common occupational hazard in the United States (Henderson, Testa,
& Hartnick, 2011; OSHA, 2011). The National Institute on Deafness and Other Communication
Disorders (NIDCD) estimates that 26 million people between the ages of 20 and 69 (15% of the
United States population) have high frequency hearing loss that may be caused by recreational
noise exposure including hobbies like woodworking, target-shooting and hunting, attending
concerts or playing in a band (NIDCD, 2008).
Certain industries are particularly susceptible, such as farming, military, aviation and
manufacturing. Although hearing protection and hearing-loss prevention programs are effective
at curtailing NIHL, instances occur, particularly within certain facets of national security and
industry, whereby the noise exceeds the protective device’s capability, rendering unavoidable
cochlear damage. For instance, the maximal noise attenuation of 24 to 34 dB against heavy
weapon noise was demonstrated by the combined use of earmuffs and earplugs (Paakkonen,
Lehtomaki, Myllyniemi, & Hamalainen, 2000), but with noise as high as 182 dBP1 as with light
anti-tank weapons (Humes, Joellenbeck, & Durch, 2005), hearing protection devices (HPDs) are
limited in their efficacy. Although most of the noise exposure in the military is below the
damaging level of impulse noise of fired weapons, the range of intensities reaches dangerous
levels at prolonged exposures: armored personnel carriers – 85 to118 dBA, army helicopters –
101to106 dBA, Abrams tank – 93 dBA when idle and 117 dBA when traveling at maximum
speed (Humes et al.). Additionally, a disparity exists between the laboratory attenuation provided

1. The true peak of a brief impulse sound can be measured using the fast-acting peak setting of a
sound level meter; when measured this way, its intensity unit is dBP.
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by HPDs and the actual “real world” attenuation achieved. Bjorne, Albery and McKinley (2006)
demonstrated that in aircraft carrier flight deck crew, who work as many as 16 hours daily amid
aircraft noise levels of 130-150 dBA, the estimated attenuation of dual HPDs (earmuffs and
earplugs) was only 0-6 dBA because of lack of compliance with the use of HPDs as well as
improper use of HPDs.
As expected, NIHL is widespread in the military. The United States (US) Department of
Veterans Affairs reports that NIHL and tinnitus are the most commonly reported disabilities
(Office of Naval Research, 2010). In 2012, 774,384 veterans received compensation for hearing
loss, the second most prevalent service-connected disability after tinnitus, with 69,326 of them
being new cases (VA, 2013). Beyond the military, NIHL has been one of the most prevalent
occupational health concerns in the United States over the last 25 years with approximately 30
million Americans exposed to hazardous noise in the workplace (OSHA, 2011).
Given that the mammalian cochlea is unable to replace lost inner and outer hair cells
(OHCs), hearing loss due to noise trauma frequently results in irreversible hearing impairment
that often is accompanied by a reduced quality of life. For these reasons, protecting the inner ear
from irreversible degeneration is of high priority in research and clinical objectives.
Pathogenesis
Noise-induced cochlear damage is a multifaceted process involving multiple cell death
pathways (Figure 1). Two known contributing modes of NIHL cell death are apoptosis and
necrosis. Apoptosis is an active cell death pathway, one that requires a continuous supply of
energy for a systemic disassembly of cell function. Necrosis, conversely, is a passive cell death
pathway that is associated with cellular energy deprivation. Apoptosis is morphologically distinct
from necrosis. Nuclear condensation and fragmentation are morphologic characteristics of
apoptosis, whereas nuclear swelling, leading to eventual rupture, is a common morphological
2

feature of necrosis. Although necrotic cell death has been found to coexist with apoptosis,
apoptosis was shown to be responsible for the expansion of the cochlear lesion (Hu, Henderson,
& Nicotera, 2002). Morphologic examination of chinchilla OHC nuclei found mainly apoptosis
involvement (i.e., condensation and fragmentation). Additionally, the detection of activated
caspase-3, a critical protease responsible for initiating irreversible processes that result in
apoptotic death, further implicates the apoptotic pathway as primary in the progression of OHC
loss from exposure to intense sounds. Necrosis related changes (e.g., swollen nuclei) accounted
for a small portion of the overall OHC damage in the Hu et al. study.
Alternatively, according to Yang, Henderson, Hu, and Nicotera (2004), apoptosis is the
predominant death pathway only during the early expansion of cochlear lesions (1 and 4 days
after exposure); at later stages (30 days after exposure), no statistical difference exists between
apoptosis and necrosis. In contrast, Bohne, Harding, and Lee (2007) found that the apoptotic and
necrotic death pathways infrequently occurred and that a third death pathway, one that is
morphologically distinct from the other two pathways, occurs much more commonly in response
to noise exposure. Using a method of microscopic examination that is different from the one
employed by Yang et al., Bohne et al. found that the third death pathway’s morphologic markers,
with respect to the condition of the plasma membrane, the appearance of the nucleus and the
distribution of debris in the organ of Corti, were more commonly occurring markers following
moderate exposure to a 500 or 4000 Hz octave band noise (OBN). Although these investigators
identified a third cell death pathway, along with evidence regarding its predominance, they
acknowledged that the pathway’s underlying processes remain unknown.
Mechanical damage, such as broken or fused stereocilia, buckling pillar cells and
glutamate excitotoxicity, whereby dendritic terminals of afferent auditory nerves swell and
rupture, has been linked to temporary threshold shift (TTS) (Nordmann, Bohne, & Harding,
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2000; Patel, Stamat, Zdanski, Ebert, & Prazma, 2008). The overwhelming research evidence
links oxidative stress as a precursor to both apoptotic and necrotic noise-induced permanent
cochlear injury. Noise at excessive levels has been shown to have metabolic consequences in the
cochlea. Overexposure leads to the mitochondrial production of reactive oxygen species (ROS),
along with other free radical molecules in the cochlea (Ohinata et al., 2000a). The OHCs require
much energy, largely because of their motility. Exposure to intense noise places especially high
demands on mitochondria to generate large amounts of energy through aerobic respiration, a
series of reactions used in the synthesis of adenosine triphosphate (ATP), a primary form of
cellular energy. This intense metabolic activity uses large amounts of oxygen and produces large
quantities of unwanted superoxides. ROS is a highly unstable oxygen-based byproduct that arises
from the electron transport chain during aerobic respiration (Le Prell, Yamashita, Minami,
Yamasoba, & Miller, 2007).
The ROS generated under normal metabolic circumstances, and in low concentrations, is
an important signaling molecule (e.g., for cell division, migration and contraction), but high
levels of ROS contribute to several negative outcomes (Porrier, 2010), beginning with lipid
peroxidation (Ohinata et al., 2000a). Lipids are major components of the cell membrane; their
deterioration leads to cell death by necrosis. Furthermore, ROS-triggered lipid peroxidation from
noise exposure, and its byproduct 4-hydrox-2-noneal (4-HNE), correlate with increased auditory
brainstem response (ABR) thresholds and OHC loss (Yamashita, Jiang, Schacht, & Miller,
2004). Lipid peroxidation and 4-HNE disrupt calcium regulation and mitochondrial function,
leading to caspase activation and apoptosis (Camandola et al., 2000). Another byproduct of lipid
peroxidation, isoprostane, is a potent vasoconstrictor that reduces cochlear blood flow (Miller,
2003). The resultant ischemia further exacerbates overtaxed mitochondria by decreasing the
oxygen supply, thereby decreasing their efficiency so increased ROS production occurs
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(Henderson, Bielefeld, Harris, & Hu, 2006). On the cochlear level, the noise-induced increase in
isoprostane formation is hypothesized to correlate with vasoconstriction in cochlear capillaries
and cell death. Isoprostane levels in the organ of Corti correlate with hair cell loss and threshold
shift (Ohinata et al., 2000a). An increase in pericytes around strial capillaries serves as further
evidence of the dramatic change in cochlear blood flow in response to loud sounds (Shi, 2009).
Deoxyribonucleic acid (DNA) damage is an additional consequence of oxidative stress
and increased ROS production. The 8-hydroxy-2P-deoxyguanosine levels in rats measured after
noise exposure confirm an interruption in gene expression; the time course of these levels
corresponds with the time course of hearing loss as defined by ABR and distortion-product
otoacoustic emissions (DPOAEs) (Van Campen, 2002).
Not only does oxidative stress commence immediately following noise exposure, but also
it accumulates over time. Oxidative species continue to accumulate over a period of 14 days after
noise exposure, with peak accumulation occurring between 7 and 10 days post exposure
(Yamashita et al., 2004). Hair cell death continues for up to thirty days after noise exposure
(Hamernik, Turrentine, Roberto, Salvi, & Henderson, 1984). DNA damage continues for eight
hours after noise exposure and peaks at the same time as the peak in threshold shift (Van
Campen, 2002). The protracted nature of NIHL pathogenesis, the long-term expansion of a
cochlear lesion from the continued production of ROS and the self-perpetuating lipid
peroxidation process, have led investigators to examine the utility of delayed interventions and
the rescue aspects, as well as preventive aspects, of otoprotective agents.
Intervention Prospects
All the evidence indicating free radicals to be essential in triggering apoptotic and
necrotic events underscores the need for an early intervention that blocks or scavenges free
radicals. Several endogenous defense mechanisms that are in place for the neutralization of toxic
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free radicals include superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH). SOD,
an enzyme that speeds up the breakdown of superoxides such as ROS into the less toxic
components of oxygen and hydrogen peroxide, is distinguished by its main location. In humans
and mammals, SOD1 is found in cytoplasm, SOD2 is found in mitochondria, and SOD3 is found
in extracellular areas; High levels of SOD1 occur in cochlear tissues including the organ of Corti
and stria vascularis. CAT, another key enzyme in the defense network that is found in the
cochlea, speeds up the decomposition of hydrogen peroxide, a byproduct of SOD breakdown,
into water and oxygen (Campbell et al., 2011). GSH protects against electron leaks by donating a
hydrogen atom to free radicals in an effort to stabilize them. The process, catalyzed by
glutathione peroxide (GPx) leaves GSH in an oxidized state, causing it to bond with another
reactive GSH to form glutathione disulfide (GSSG). Enzyme glutathione reductase reduces
GSSG back to GSH. One symptom of oxidative stress is the increased ratio of GSSG to GSH.
Under normal conditions, GSH is the predominant form, with low levels of GSSG being present.
Of the 8 major GPx isoforms, GPx1 is the major isoform of the catalyst found within the cochlea
and is highly expressed in the organ of Corti (stria vascularis and spiral ligament) and spiral
ganglia (Campbell et al., 2011).
The biological mechanisms of NIHL suggest several points of possible intervention along
the course of pathogenesis, leading to a number of different approaches to intervention and to the
reduction of the damaging effects of noise (Campbell et al., 2011; Lynch & Kil, 2005). Given the
apparent self-perpetuating nature of lipid peroxidation in the NIHL process, lipid restoration
mechanisms have been examined for their potential to serve as intervention approaches. AcetylL-carnitine (ALCAR), a precursor to acetylcoenzyme A (acetyl-CoA), a mitochondrial energy
substrate, and L-carnitine, shuttle lipid substrates into the mitochondria, thereby enhancing ATP
production and respiration efficiency. ALCAR has been shown to restore mitochondrial lipid
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cardiolipin, further restoring mitochondrial integrity (Kopke, 2002). And N-acytylcystein
(NAC), successfully attenuated, in the organ of Corti, cochlear lateral wall, and modiolar core,
the increased 8-isoprostane levels associated with excessive noise exposure; 8-isoprostane is a
lipid peroxidation product and a biomarker of oxidative stress(Ohinata et al., 2003).
Similarly, apoptotic signaling pathways represent another avenue for intervention from
noise-induced damage. Anti-apopoptic agents disrupt mitogen-activated protein kinase (MAPK)
cell death signaling through peptide inhibition of c-Jun N-terminal Kinase (JNK). Subjects who
subcutaneously received CEP-1347, a JNK inhibitor, for two weeks after noise exposure showed
significantly less permanent threshold shift (PTS) than controls (Pirvola, 2000). Similarly,
chinchillas who received KX1-004, an inhibitor of Src protein tyrosine kinase, exhibited less
PTS and less OHC damage than the control animals (Harris, 2005).
Evidence of cochlear ischemia involvement, both in increased ROS production as well as
in OHC loss, places interest in agents that prevent hypoperfusion. Investigators have attempted
to increase cochlear blood flow by increasing systemic blood flow via dilation of cochlear blood
vessels as well as by blood thinning. But mixed results on NIHL protection have been seen in
studies on drugs that promote blood flow (Henderson, 2006).
NIHL otoprotection research also has focused on antioxidants, which scavenge
superoxides and convert them to less dangerous molecules. Antioxidants, naturally occurring
compounds, can be found in food and, therefore, are not foreign to the human body (Campbell et
al., 2011). Exogenous antioxidants have the ability to produce endogenous glutathione, thereby
offsetting the effects of an overwhelmed endogenous antioxidant defense system elicited by ROS
overproduction. Antioxidant enzymes protect the cochlea by reducing hydroperoxide formation.
Partial otoprotection has been achieved from dietary antioxidants such as Vitamins A, E and C.
Antioxidants that reduce cell death and NIHL include reduced glutathione monoethyl ester,
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GSHE (Hight, McFadden, Henderson, Brukard & Nicoreta, 2003; Kopke, Coleman, Liu,
Campbell & Riffenburgh, 2002; Ohinata, Yamasoba, Schacht & Miller, 2000b); Ebselen, a
glutathione mimic and catalyst enzyme that is unconsumed during detoxification reactions
(Lynch, Gu, Pierce, & Kil, 2004; Pourbakht & Yamasoba, 2003;); N-acetylcystein (NAC) a
glutathione precursor and ROS scavenger (Ohinata, Miller & Schacht, 2003); allopurinol
(Seidman, Babu, Tang, Naem, & Quirk, 2003); mannitol, a scavenger of the hydroxyl radical
(Yamasoba, Schacht, Shoji, & Miller, 1999).
Although they differ in the specific mechanism of action and pathway affected,
antioxidants as a group have high safety profiles. Their favorable therapeutic indices result in
efficacy at lower doses. Although several non-antioxidant agents have been found to be
efficacious in animal studies, they are not easily translated to humans because they are rendered
unsafe or are clinically infeasible in humans. Some agents require expensive formulation or
include unsafe and inconvenient delivery requirements (e.g., round window injection).
Current research is focusing on a particular antioxidant called D-Methionine (d-Met),
shown to mitigate oxidative stress generated by excessive noise and to prevent sensory cell
death. D-Met acts as an indirect antioxidant, increasing mitochondrial glutathione levels by
preventing their efflux, thereby keeping a healthy ratio of GSSH to GSH, and by protecting
levels of other antioxidant enzymes. D-Met also is a direct antioxidant that efficiently scavenges
free radicals because unlike other amino acids, its oxidation is reversible (Vogt, 1995).
D-Met’s efficacy and safety for various physiological aspects have been studied for
decades. An essential amino acid that easily penetrates through cell membranes, D-Met is
considered to be a safer compound than its L isomer, with well characterized pharmacokinetics
and a longer period of bioavailability as a result of an increased serum half-life. The World
Health Organization (WHO) considers d-Met to be an essential drug for treating acetaminophen
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toxicity (WHO, 2009). The compound has been available over-the-counter for decades for
urinary acidity and dermatitis and has been shown to be free of side effects. D-Met can be found
in high quality dietary proteins and in fermented products such as cheese and yogurt; the
fermentation process transaminases the L isomer into the D isomer. Unlike other compounds that
exhibit poor bioavailability and therefore require systemic or local injection, oral formulation of
d-Met already is in existence (Campbell et al., 2007).
The purpose of this systematic literature review was to review d-Met’s efficacy in
reducing threshold shifts as well as in producing biochemical and physical changes in animal
studies vis-à-vis the administration paradigm (preloading, rescue and a combined approach), dMet dose quantity and the number and schedule of administrations.
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Figure 1. NIHL pathogenesis and endogenous defense mechanisms.
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METHODS
Animal studies evaluating d-Met efficacy in reducing NIHL and its associated
biochemical changes were reviewed (Appendix A).
Database Search
Comprehensive searches utilizing databases via the Mina Rees Library of the Graduate
Center of The City University of New York were performed to identify relevant publications to
be included in this review. A global search was performed between the dates of November, 2011
to December, 2011; the most recent search was accomplished in March, 2014 for the purpose of
identification of the latest publications. The search for relevant literature took place on the title,
abstract and full-text levels throughout the electronic and manual databases. The following
databases were employed to search for relevant studies: Academic Search Complete, EbscoHost,
Science Direct, PubMed Central, Scopus, and Google Scholar. Some articles not available
directly via the Mina Rees Library were requested through the Interlibrary Loan. Additionally,
when an article was found to be relevant to the topic of interest, the article’s reference list was
searched for relevant studies not identified in the direct database search. The search was limited
to articles published in English.
To identify pertinent studies in the existing literature, a search was conducted using various
combinations of the following key words: antioxidant, noise induced hearing loss, d-methionine,
d-met, oxidative stress, apoptosis, necrosis, hearing, hearing loss, hearing impairment,
otoprotection, and protection. The key words "d-methionine" and "noise induced hearing loss"
were used consistently throughout the search. The terms "oxidative stress" and "hearing loss"
were at times included in the search strings using Boolean operator "NOT" to limit retrieval of
irrelevant studies. No limiters were applied for date of publication.
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Evaluation Procedure to Limit Articles Reviewed
A rating of strength of evidence was applied to the body of research reviewed. The rating
system used was based on Cox’s (2005) description of levels of evidence. Level 1, the highest
level of evidence, comes from systematic reviews and meta-analyses of randomized controlled
trials or other high-quality studies. Level 2 evidence comes from randomized controlled trials
such as those more commonly seen in drug or other treatment efficacy studies. Level 3 studies
involve intervention, but the methods do not include random assignment of participants to
treatment groups. Level 4 studies do not include a treatment or intervention. These studies
involve the observation of a group or groups of subjects with a given condition or treatment over
time. Level 5 evidence comes from reports of individual cases with given conditions or
treatments. Lastly, Level 6 evidence comes from expert opinion based on experience and/or
knowledge of the subject. Cox’s levels of evidence were applied to restrict articles reviewed to
Level 3 or better studies.
Types of Outcome Measures Reviewed
The following (any one or combination) represent primary outcomes of d-Met treatment that
were reviewed: (a) hearing loss (as defined by the authors of the original studies); (b)
biochemical mechanisms including SOD activity and levels, CAT activity and levels, LPO
levels, and quantity of OHCs. The following (any one or combination) represent the variables
associated with d-Met treatment: (a) type of animal model; (b) noise exposure (type, length and
intensity); (c) delivery method and timing of d-Met administration; (d) d-Met administration
paradigm (preloading, rescue, combined approach); (e) total number of d-Met doses
administered; and (f) stimulus used in ABR threshold measurements.
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RESULTS
Although a number of otoprotective agents are being studied for their efficacy in the
prevention and rescue from NIHL, d-Met is the only agent on which a US government agency
(the US Department of Defense) is funding an investigation and is the only agent that currently is
in Phase III human clinical trials. D-Met’s efficacy in reducing NIHL has been demonstrated in a
number of animal models. Of the 10 animal studies reviewed, 3 focused on d-Met’s prophylactic
value (the ability to prevent hearing loss after noise exposure, also called preloading); 3 studies
examined d-Met’s efficacy as a rescue agent (its ability to reduce NIHL when administered after
the noise exposure); and 4 studies adopted a combined approach (d-Met administration prior to
as well as post noise exposure).
Research Design
Of the 10 animal studies included in this review, 50% used chinchilla Laniger animals
(male animals in 3 studies and female animals in 2 studies). The male chinchillas ranged in age
from 6 weeks to 3 years whereas the female chinchillas were adult age. Guinea pigs were used in
30% of the studies (Hartley-strain albino guinea pigs in 2 studies and Dunkin-Hartley guinea pig
in 1 study). The remaining 20% of the studies were done on the C57BL/6 mouse (see Table 1).
Table 1
D-Met NIHL Investigations Categorized by Animal Species
Animal model
Chinchilla Laniger

Study
Claussen et al. (2013)
Campbell et al. (2011)
Campbell et al. (2007)
Clifford et al. (2011)
Kopke et al. (2002)

Guinea pigs

Cheng et al. (2008)
Alagic et al. (2011)
Lo et al. (2013)
Reweska et al. (2012)
Samson et al. (2008)

C57BL/6 mice
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Table 2 shows the type of noise exposure employed in these ten animal studies. The noise
exposure in 70% of these studies involved an octave band noise (OBN) centered on 4000 Hz at
105-110 dB SPL. In 1 study, the OBN was centered at 12000 Hz at 100 dB SPL and in 2 studies,
the noise was a broadband noise (BBN) at 105 dB SPL. The typical duration of exposure varied
between 4 and 8 hours, with 60% employing an exposure duration of 6 hours. The two studies
that focused on a temporary threshold shift, as opposed to PTS, included shorter exposure
durations of 10 minutes in the Cheng, Liu, Young, Hsu, and Lin-Shiau (2008) investigation and
45 minutes in the Alagic, Goinly, and Canlon (2011) investigation.
Table 2
Type of Noise Exposure in Animal Studies on D-Met and NIHL
Type of noise
OBN centered at 4000 Hz

OBN centered at 12000 Hz
BBN (125 to 15000 Hz)

Study
Claussen et al. (2013)
Campbell et al. (2011)
Campbell et al. (2007)
Clifford et al. (2011)
Kopke et al. (2002)
Reweska et al. (2012)
Samson et al. (2008)
Alagic et al. (2011) – TTS at 45 minutes
Cheng et al. (2008) – TTS at 10 minutes
Lo et al. (2013)

D-Met Administration
Administration was intraperitoneal in 90% of the 10 studies. In one study, the d-Met
solution was injected through the round window of the cochlea. The timing of administration of
d-Met is shown in Table 3. Note that in the preloading studies, d-Met was administered between
3 days prior the noise exposure and 1 hour prior to the noise exposure. A single dose of d-Met
was administered in 2 of the 3 preloading studies (Alagic et al., 2011; Cheng et al., 2008) and 5
injections of d-Met were administered in 1 of the 3 preloading studies (Claussen et al., 2013). In
the rescue studies, d-Met administrations commenced from 1 hour post to 7 hours post noise
14

exposure, continuing through 2 days post noise exposure (at 12 hour intervals) for a total of 4-5
administrations. In the 4 studies employing combined preloading and rescue administrations, the
pre-exposure d-Met administration occurred between 2 days and 1 hour and the post-exposure dMet administration occurred between 2 and 3 days. All of these studies included d-Met
administration at 1 hour prior to noise exposure and at 1 hour post exposure; and all involved
administration of d-Met at 12 hours post noise exposure, with the exception of Samson et al.
(2008) who administered d-Met on a daily basis post noise-exposure. The total number of d-Met
administrations, both before and after noise exposure, differed considerably among the
preloading and the combined approach studies, and was very similar among the rescue studies
(see Table 3).
Table 3
D-Met Administration Paradigm, Total Number and Schedule/Dose of Administrations

Study
paradigm
Preloading

Rescue

Both

Investigation
Alagic et al. (2011)
Claussen et al. (2013)
Cheng et al. (2008)
Campbell et al, (2011)
Campbell et al. (2007)
Lo et al. (2013)

Total
number
of doses
1
5
1
4
5
5

Starting time of
pre-exposure
administration
90 minutes prior
2, 2.5 or 3 days prior
1 hour prior
3, 5, 7 hours post
1 hour post
1 hour post

Ending time of
post-exposure
administration

2 days
2 days
2 days

Clifford et al. (2011)
Kopke et al. (2002)
Reweska et al. (2012)

10
10
8

2 days prior
2 days prior
1 hour prior

2 days
2 days
3 days

Samson et al. (2008)

4

1 hour prior

2 days

Individual
Dose
5 ml
200 mg/kg
300 mg/kg
200 mg/kg
200 mg/kg
200, 400, & 600
mg/kg
12 mg/kg
200 mg/kg
100, 200, & 400
mg/kg
400 mg/kg

Of the 10 animal studies, 80% limited their examination to one dosing quantity, varying from 12
mg/kg to 600 mg/kg and 20% compared the effects of different dosing quantities (see Table 3).
The dose was 200 mg/kg in a majority of the studies (60%) and was 400 mg/kg in 30% of the
studies.
15

Auditory brainstem response (ABR) testing was used to evaluate the efficacy of d-Met. In
80% of these studies, tonal stimuli were employed, and in the remainder of the studies, click
stimuli were employed (see Table 4). Of the tonal ABR studies, half examined ABR threshold
shifts between 2000 and 8000 Hz. Alagic et al. (2011) examined ABR threshold shifts at 8000
Hz and higher.
Table 4
Stimuli Used in the ABR Threshold Studies of D-Met Efficacy

Stimulus frequency (Hz)
2000, 4000, 6000, 8000

8000, 12000, 16000, 20000
4000, 8000
8000
Click

Study
Clifford et al. (2011)
Campbell et al. (2011)
Campbell et al. (2007)
Claussen et al. (2013)
Kopke et al. (2002)
Alagic et al. (2011)
Samson et al. (2008)
Rewerska et al. (2012)
Cheng et al. (2008)
Lo et al. (2013)

D-Met Efficacy
All of the studies demonstrated d-Met efficacy in preventing or reducing hearing loss
associated with noise exposure (Appendices B-D). The study findings differed with respect to the
frequency of the effect, dose that was efficacious, and time at which the effect first became
significant.
Although hearing recovery was demonstrated at all frequencies investigated, the degree of
recovery was least at 6000 Hz. The low-dose preloading paradigm failed to demonstrate a
significant reduction in hearing loss at 6000 Hz (Alagic et al., 2011). Similarly, the rescue model
provided evidence for d-Met efficacy at 2000 Hz and higher, excluding 6000 Hz (Campbell,
2011). On the other hand, efficacy was established at 6000 Hz in the Campbell et al. (2007)
rescue study. And Alagic et al. found that significant recovery at 12000 Hz occurred immediately
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after the noise exposure but then disappeared at one hour post exposure, in contrast with the
persistent recovery seen at 8000, 16000 and 20000 Hz.
D-Met efficacy was demonstrated for all doses investigated. Dose-effects on D-Met efficacy
was addressed by two studies (Lo et al., 2013; Reweska et al., 2012). Lo et al. in their rescue
study, found significant hearing recovery for the higher doses (400 and 600 mg/kg) but not for
the lowest dose (200 mg/kg). Similarly, Reweska et al. in their combined approach study, found
greater protection from NIHL at higher doses than lower doses of d-Met: at 100 mg/kg,
significant hearing recovery did not extend past 1 day post noise exposure; at 200 mg/kg,
significant recovery was limited to 7 days after noise exposure whereas significant recovery from
the highest dose of 400 mg/kg was seen even at 14 days post noise exposure
The variation among studies with a combined approach administration paradigm was
greatest on the number of administrations, ranging from 4 administrations in the Samson et al.
(2008) investigation to a total of 10 d-Met administrations in the Clifford et al. (2013) and Kopke
et al. (2002) studies. Of note, the studies with more d-Met administrations exhibited d-Met
efficacy at one week post noise exposure (Clifford et al.; Kopke et al.; Reweska et al., 2012)
whereas Samson et al. did not demonstrate efficacy at that examination interval.
Efficacy By administration paradigm
All three preloading studies demonstrated d-Met efficacy. The findings of the two studies
that administered a single dose of d-Met (Alagic et al., 2011; Cheng et al., 2008) demonstrated a
reduction in the threshold shift immediately, at 1-2 hours after, and at one day after noise
exposure. Alagic et al. did not examine prophylactic efficacy beyond 1 day post exposure. The
results of Cheng et al. demonstrated lack of significant preloading efficacy at seven days after
noise exposure; they did not measure threshold shift at one day post noise exposure. Although
Claussen et al. (2013), who administered 5 doses of d-Met prior to the noise exposure, failed to
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demonstrate a significant beneficial d-Met effect at 1 day post exposure, they did find a
significant improvement in the threshold shift at 3 weeks post exposure in the group that
commenced their d-Met administrations earlier – at 3 days but not at 2 or 2.5 days prior to the
exposure.
The rescue studies focused their examination of hearing recovery at two to three weeks
post exposure. Campbell et al. (2011), who were the only investigators to examine d-Met
efficacy at one day post exposure, did observe a significant rescue at that examination time
interval. In all three rescue studies (Campbell et al., 2011, 2007; Lo et al., 2013), hearing
recovery was significant at later time points. Significant recovery was demonstrated at 2 weeks
post exposure for the 400 and 600 mg/kg doses but not for the 200 mg/kg dose (Lo et al.) and at
3 weeks post exposure (Campbell et al. 2007, 2011). Both studies that examined d-Met efficacy
in hearing loss recovery at the 3-week post-exposure mark limited their examination to the 200
mg/kg dose. Campbell et al. (2007) demonstrated significant hearing rescue at each examined
frequency, but they (2011) found significant recovery to be limited to 2000 and 4000 Hz at all
three delay intervals and limited to 8000 Hz only for the group that commenced treatment 3
hours after exposure; significant hearing recovery was not demonstrated at 6000 Hz for any of
the d-Met administration delays (3, 5 or 7 hours post exposure).
All four studies that administered d-Met both prior to and post noise exposure (combined
approach) demonstrated benefit of the drug in attenuating NIHL. Reweska et al. (2012) and
Samson et al. (2008) both limited their pre-treatment to a single administration. Whereas
Reweska et al. found a significant reduction in threshold shift at one day post noise exposure for
each dosing level (100, 200 and 400 mg/kg), Samson et al. did not despite sharing the species,
type and length of noise, and one dose level (400 mg/kg) with Reweska et al. In the three studies
that examined d-Met efficacy at one week post exposure, significant recovery (for various doses)
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was demonstrated. Two studies showed d-Met efficacy at 3 weeks after exposure, with Kopke et
al. (2002) demonstrating efficacy at each of the examined frequencies (2000, 4000, 6000 and
8000 Hz) and with Clifford et al. (2011) showing significant rescue with their low dose (12
mg/kg) only at 4000 Hz.
Of the 7 studies that included preloading, 4 examined the threshold shift immediately (12 hours) post exposure. Of those, only 50% demonstrated d-Met efficacy at that time point.
Cheng et al. (2008) found a noise-induced threshold shift of only 4 dB to a click ABR,
significant in comparison with the saline group’s threshold shift of 15 dB. Alagic et al. (2011)
found significant reduction in hearing loss immediately after exposure at each of the examined
frequencies (8000, 12000 16000 and 20000 Hz) with threshold shifts immediately after noise
exposure of 4-24 dB in the d-Met group versus 14-36 dB in the control group. Five studies
examined d-Met efficacy at 1 day after exposure but significant hearing recovery was
demonstrated in only two of these. Alagic et al. demonstrated that reduction in hearing loss
found immediately post exposure was successfully extended to one day after exposure at all
frequencies examined, with the exception of 12000 Hz. Reweska et al. (2012) found significant
hearing recovery at 8000Hz (the only frequency studied) at one day after exposure for each of
the three doses (100, 200 and 300 mg/kg) examined.
In all three studies that examined d-Met efficacy at seven days after exposure, efficacy
was demonstrated. Reweska et al. (2012) demonstrated that the hearing recovery for all 3 doses
at 1 day after exposure became limited to only the highest dose levels (200 and 400 mg/kg) at 7
days after exposure. Similar findings at 7 days post exposure were obtained by Kopke et al.
(2002) at each of the examined frequencies (2000, 4000, 6000 and 8000 Hz) and by Clifford et
al. (2013) at 4000 Hz but not at 2000, 6000, or 8000 Hz.
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All five studies that examined hearing recovery at two weeks after exposure
demonstrated d-Met efficacy at that time interval. Clifford et al. (2013) showed recovery at 4000
and 8000 Hz but not at 2000 or 6000 Hz. Kopke et al. (2002) demonstrated efficacy at every
examined frequency (2000, 4000, 6000 and 8000 Hz). Efficacy at 14 days after noise exposure
was limited to 4000 Hz in the Samson et al. (2008) study. Both dose-effect studies demonstrated
efficacy of higher doses at this time point: Reweska et al. (2012) showed that only the 400 kg/mg
dose provided significant hearing recovery and Lo et al. (2013) showed that significant recovery
was limited to the 400 and 600 mg/kg doses.
Half the studies examined the extent of threshold shifts three weeks after noise exposure.
Whereas Claussen et al. (2013), Campbell et al. (2007) and Kopke et al. (2002) exhibited hearing
recovery at all the examined frequencies (2000, 4000, 6000 and 8000 Hz), significant threshold
recovery at 21 days post noise was limited to 2000, 4000, and 8000 Hz in the Campbell et al
(2011) study. Clifford et al. (2013) found hearing recovery at 3 weeks after exposure at 2000 and
4000 Hz but not at 6000 or 8000 Hz.
Biochemical and Physical Effects
In light of knowledge that cells counteract oxidative insult by employing a complicated
enzymatic defense system (Henderson et al., 2006), several of the animal studies that examined
d-Met efficacy vis-à-vis ABR threshold shift also looked at the antioxidant’s effect on
biochemical mechanisms induced by excessive noise (summarized in Appendix E).
Reweska et al. (2012) found a significant increase in SOD activity levels at 7 and 14 days
after exposure only for the 400 mg/kg dose; lower doses of 100 and 200 mg/kg did not scavenge
free radicals as effectively. Samson et al. (2008), who limited their examination to the 400 mg/kg
dose, found that d-Met effectively counteracted the time-dependent increases in SOD quantities
in response to noise. In the d-Met group, the expected peak of SOD at 7 days post noise was
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significantly attenuated to 200 units/mg in the d-Met treated group versus 300 units/mg in the
saline noise-exposed group. Since superoxide formation increases concomitantly with increases
in free radicals, a lower quantity level of SOD as a result of d-Met treatment provides evidence
to effective scavenging by the antioxidant.
Reweska et al. (2012) observed a significant decrease in noise-induced changes in CAT
activity for both the 200 and 400 mg/kg doses, but not for the 100 mg/kg dose at 7 days post
exposure. The decreased CAT levels for the higher doses did not persist at fourteen days after
exposure. Similar findings for CAT activity were obtained by Samson et al. (2008) at seven days
post exposure.
Samson et al. (2008) further demonstrated d-Met efficacy in reducing LPO levels at seven
days after exposure. Cheng et al. (2008), who examined d-Met efficacy for TTS reduction,
confirmed significant decreases in LPO levels immediately after and at one day post noise
exposure. Significant d-Met effects on LPO were not observed at 7 days after the limited
exposure of 10 minutes in the Cheng et al. study.
Two studies documented the effect of d-Met on noise-induced hair-cell loss. Kopke et al.
(2002) found that the saline group experienced loss of the OHCs, an average of approximately
60% for the 4000 Hz to 10000 Hz regions. In contrast, d-Met administration significantly limited
the OHC loss, with cytocochleograms showing less than 10% loss for the d-Met group Campbell
at al. (2011) similarly found that whereas saline groups typically exhibited OHC reductions
resulting from noise exposure (leading to only 64-74% remaining at the regions between 2000
and 8000 Hz,) 90-98% of the OHC population was preserved in all d-Met groups, regardless of
onset of d-Met administration (3, 5 or 7 hours post exposure). Claussen et al. (2013)
demonstrated similar OHC rescue with d-Met administration beginning at 2.5 and 3 days prior to
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noise exposure. OHC rescue failed to be significant with the group that commenced d-Met
treatment at 2 days prior to noise exposure.
Although the inner hair cells IHCs are less affected than the OHCs by noise exposure,
Kopke et al. (2002) found a significant d-Met attenuation of IHC loss. The IHC loss from noise
exposure in the saline groups ranged from 10-24% (with loss increasing with increasing distance
from the apex) but was predominately absent in the d-Met groups.
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DISCUSSION
The efficacy of d-Met in reducing NIHL and in limiting noise-generated biochemical
changes was demonstrated by all 10 reviewed studies. Yet, although efficacy was shown by each
reviewed investigation, a consensus with regard to the optimal dose amount, number of doses or
the best administration paradigm (preloading, rescue or a combined approach) and timing was
not found by the current review.
The dosing question remains largely unanswered. Evidence supports the efficacy of a
low-dose paradigm (Clifford et al., 2013) whereby a dose of only 12 mg/kg demonstrated
hearing recovery at 1, 2, and 3 weeks after exposure to noise. Yet a significantly higher dose of
400 mg/kg (Samson et al., 2008) failed to show efficacy at the same time interval and frequency
although the combined approach administration paradigm was employed with both doses.
Perhaps the discrepant findings relate to the total number of doses administered. Clifford et al.
administered a total of 10 doses, with 5 doses prior to noise commencing 2 days prior to
exposure whereas Samson et al. administered a total of 4 doses with only a single dose at 1 hour
prior to noise exposure. The results of the one study (Reweska et al., 2012) that compared dosing
amounts while controlling for administration paradigm and total number of doses supports the
conclusion that d-Met efficacy increases with higher doses. Reweska et al. showed that efficacy
for the 100 mg/kg dose was limited in duration to 1 day post exposure whereas the efficacy for
the 400 mg/kg dose persisted at the two week mark. Lo et al. (2013), in their rescue study that
also controlled for the total number doses administered, similarly provided evidence that d-Met
efficacy occurred with higher doses (400 and 600 mg/kg) but not for the lower dose (200 mg/kg).
As mentioned by Clifford et al., liver function studies serve as useful biomarkers for the efficacy
of d-Met for acetaminophen overdoses; a similar biomarker gold standard to guide optimal dMet dosage to direct treatment and dosing for NIHL is currently unavailable.
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One of the most salient findings of the review was the lack of effect of administration
paradigm on d-Met efficacy; studies with and without preloading doses demonstrated
comparable benefit from d-Met application. This is a promising finding since in some settings,
noise exposure may be unexpected or unpredictably exceed the protection offered by HPDs
(Bjorne et al., 2006). Furthermore, as evidenced by Campbell et al. (2011), a delay in the postnoise administration of d-Met from 3 to 7 hours after exposure did not adversely affect the
benefit of d-Met in protecting against NIHL. Of interest for future studies is the effect of
increased time delay for initial d-Met application as a finding of d-Met benefit with increased
time delays has implications for situations in which the availability of d-Met is not immediate
(e.g., within hours of exposure). Given the evidence for protracted cochlear injury following
acoustic trauma, with OHC loss peaking at approximately seven days after noise insult, a
potential window of opportunity possibly extending to a delay of a few days for an initial d-Met
administration may exist for pharmacologic treatment to rescue cochlear cells during the period
that follows excessive noise exposure (Yamashita et al., 2004). Similarly, the efficacy
demonstrated in a preloading-only paradigm also offers great utility. The availability of an oral,
prophylactic pharmacologic agent can be of particular benefit to those in the military (e.g.,
soldiers prior to deployment into noisy environments, especially for special operation troops who
have restricted pack weights for missions). In addition to demonstrating efficacy in the reducing
threshold shifts following noise exposure, the studies reviewed also showed d-Met efficacy in
improved ROS scavenging, as evidenced by decreased levels of SOD and CAT, as well as
decreased pre-apoptotic events because of lower LPO levels.
A Phase 3 Clinical Trial, sponsored by Kathleen Campbell and her collaborators at
Southern Illinois University in collaboration with the Department of Defense, currently is
underway. The randomized, double-blind, placebo-controlled study on d-Met efficacy in
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reducing NIHL as well as noise-induced tinnitus includes 600 drill sergeants during M-16
weapons training. Each participant will receive a total of 36 doses of oral d-Met (100 mg/kg per
dose). This combined approach administration paradigm includes 6 doses prior to noise
exposure starting at 3 days prior to training, with doses continuing for 11 days during training
(and an administration interruption during a weekend in the middle of the training period) and
then 4 days of d-Met administration after training cessation. Of note is the decision to remain at
the 100 mg/kg dosing level that is significantly higher than the low-dose paradigm (12 mg/kg)
but is significantly lower than the 200 mg/kg dose in most of the efficacy studies. On the other
hand, the total number of doses scheduled to be administered in the human trial is 36 whereas the
greatest number of administrations in the animal studies was 10. Along the same lines, the
effects of noise exposure are different in humans as compared with animals. The final collection
date for the primary outcome measures is March, 2017 and the estimated trial completion date is
March, 2018.
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CONCLUSIONS
The efficacy of d-Met was demonstrated in each of the reviewed animal studies,
regardless of the dose amount or strategy in timing of d-Met administration. Should d-Met be
similarly effective in humans at reducing NIHL as it has been in animal studies to date, and
should it be approved by the Food and Drug Administration (FDA) and become available for
clinical use, then potential exists for ameliorating or preventing hearing loss from noise exposure
in millions of individuals worldwide. Of interest for future studies is the efficacy of d-Met in
attenuating NIHL for noise that more closely resembles “real world” exposure (i.e., recreational
noise or work-related noise that is not as intense as in the reviewed studies but that is more
protracted in nature, continuing for years and possibly decades). Since the 1970’s, aspirin has
been associated with heart disease prevention. Similarly, d-Met may one day be available overthe-counter and become synonymous with NIHL prevention.

26

APPENDIX A: D-MET STUDIES – PARTICIPANTS, D-MET DELIVERY, NOISE, AND
VARIABLES
Noise
Authors

Animal

Lo et al.
(2013)

N

Delivery
Frequency Intensity Time
Variables examined
method
(kHz) (dB SPL) (hours)
24 Intraperitoneal BBN (.125
105
6
ABR threshold shift
Injection
kHz - 15)
Ca2+-ATPase
Na+/K+ ATPase

Hartleystrain
albino
guinea pigs
Claussen
Male
20 Intraperitoneal
et al.
chinchilla
Injection
(2013)
Laniger (3
years old)
Rewerska C57BL/6 400 Intraperitoneal
et al. (2012) mice
Injection
(6 week
old)
Samson
Male
6 Intraperitoneal
et al.
C57BL/6
Injection
(2008)
mice (12
week old)
Campbell Male
38 Intraperitoneal
et al. (2011) chinchilla
Injection
Laniger (3
years old)

4 OBN

105

6

ABR threshold shift

4 OBN

110

8

ABR threshold shift
SOD
CAT

4 OBN

110

4

ABR threshold shift
SOD
LPO

4 OBN

105

6

ABR threshold shift
OHC loss

20 Intraperitoneal
Injection

4 OBN

105

6

ABR threshold shift

21 Intraperitoneal
Injection

4 OBN

105

6

ABR threshold shift

12 Intraperitoneal
Injection

4 OBN

105

6

ABR threshold shift
OHC loss
IHC loss

Cheng et al. Hartley16 Intraperitoneal BBN (.125
(2008)
strain
Injection
- 15)
albino
guinea pigs

105

0.17

Alagic et al. Dunkin21 Round window
(2011)
Hartley
injection
guinea pigs

100

0.75

ABR threshold shift
Ca2+-ATPase
Na+/K+ ATPase
LPO
NO
ABR threshold shift
d-Met in perilymph

Campbell Male
et al. (2007) chinchilla
Laniger (3
years old)
Clifford
Female
et al.
adult
(2011)
chinchilla
Laniger
Kopke et al. Female
(2002)
adult
chinchilla
Laniger

12
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APPENDIX B: AMOUNT AND TIMING OF THRESHOLD SHIFT (RESCUE STUDIES)
Examination interval (post noise)

Study
Campbell
et al.
(2011)

Frequency
(Hz)
2000

4000

6000

8000

Campbell
et al.
(2007)

2000
4000
6000
8000

Lo et al.
(2013)

Click

Group
(saline or d-Met
dose)
Saline
200 mg/kg (3 hrs)
200 mg/kg (5 hrs)
200mg/kg (7 hrs)
Saline
200 mg/kg (3 hrs)
200 mg/kg (5 hrs)
200 mg/kg (7 hrs)
Saline
200 mg/kg (3 hrs)
200 mg/kg (5 hrs)
200 mg/kg (7 hrs)
Saline
200 mg/kg (3 hrs)
200mg/kg (5 hrs)
200 mg/kg (7 hrs)
Saline
200 mg/kg
Saline
200 mg/kg
Saline
200 mg/kg
Saline
200 mg/kg
Control
Saline
200 mg/kg
400 mg/kg
600 mg/kg

n
10
10
8
10
10
10
8
10
10
10
8
10
10
10
8
10
10
10
10
10
10
10
10
10
6
6
6
6
6

1-2
hours
------------------------------

1
day
30
20
20
20
50
50
50
40
42
40
42
35
45
32
40
30
--------------

7
days 14 days
-------------------------------------------------0.2
-9.6
-9.6
-6.3*
-1.3*

21 days
20
4*
2*
5*
20
8*
8*
8*
18
0
0
2
10
9*
10
10
19
1*
21
4*
8
0*
11
2*
------

*Threshold shift is significant (p < 0.05)
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APPENDIX C: AMOUNT AND TIMING OF THRESHOLD SHIFT
(PRE-LOADING STUDIES)
Examination interval (post noise)

Study
Alagic
et al.
(2011)

Cheng
et al.
(2008)
Claussen
et al.
(2013)

Group
Frequency
(saline or d-Met
(Hz)
dose)
8000 Saline
d-Met 5 ml
12000 Saline
d-Met 5 ml
16000 Saline
d-Met 5 ml
20000 Saline
d-Met 5 ml
Click Saline
Saline-7days
300 mg/kg-all
300 mg/kg-7days
2000 Saline (2.5 days)
200 mg/kg - 2 days
200 mg/kg - 2.5 days
200 mg/kg (3 days)
4000 Saline (2.5 days)
200 mg/kg (2 days)
200 mg/kg (2.5 days)
200 mg/kg (3 days)
6000 Saline (2.5 days)
200 mg/kg (2 days)
200 mg/kg (2.5 days)
200 mg/kg (3 days)
8000 Saline (2.5 days)
200 mg/kg (2 days)
200 mg/kg (2.5 days)
200 mg/kg (3 days)

n
10
11
10
11
10
11
10
11
16
4
16
4
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

1-2
hours
14
4*
23
13*
30
19*
36
24*
15
15
4*
2
-----------------

1 day
8
2*
12
6
22
11*
27
13*
----68
56
59
42
73
59
67
65
71
60
73
53
62
51
66
49

7 days
---------1
-0
-----------------

14
days
-----------------------------

21 days
------------48
30
27
13*
54
32
29
21**
42
29
27
9**
44
28
29
12*

* Threshold shift is significant (p < 0.05)
** Threshold shift is significant (p < 0.01)
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APPENDIX D: AMOUNT AND TIMING OF THRESHOLD SHIFT
(COMBINED APPROACH STUDIES)
Examination interval (post noise)

Study
Clifford
et al.
(2013)

Frequency
(Hz)
2000

4000

6000

8000

Kopke et al.
(2002)

2000
4000
6000
8000

Reweska
et al
(2012)

8000

Samson
et al.
(2008)

8000
4000

Group (saline,
D-Met or D-Met
+ NAC)
Saline
12 mg/kg+NAC
12 mg d-Met
Saline
12mg/kg+NAC
12 mg d-Met
Saline
12 mg/kg+NAC
12 mg d-Met
Saline
12mg/kg+NAC
12mg d-Met
Saline
200 mg/kg d-Met
Saline
200 mg/kg d-Met
Saline
200 mg/kg d-Met
Saline
200 mg/kg d-Met
Saline
100 mg/kg d-Met
200 mg/kg d-Met
400 mg/kg d-Met
Saline
400 mg/kg d-Met
Saline
400 mg/kg d-Met

n
7
7
7
7
7
7
7
7
7
7
7
7
6
6
6
6
6
6
6
6
80
80
80
80
6
6
6
6

1-2
hours
66
65
71
84
93
89
96
98
97
87
93
94
65
62
86
87
95
87
86
85
22
---36
-33
--

1 day
--------------------22
10*
13*
7*
36
24
33
30

7
days
25
25
22
42
43
32*
50
53
50
46
52
47
19
11*
42
31*
49
37*
46
33*
11
11
6*
3*
25
-25
--

14 days
16
10
11
33
30
14*
40
35
25
39
37
25*
17
1*
31
18*
37
22*
38
23*
11
8
8
2*
16
7
14
5*

21
days
16
3*
6
30
13
11*
35
19
23
31
20
21
17
0*
30
8*
35
12*
33
12*
----15
-15
--

* Threshold significant (p < 0.05)
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APPENDIX E: BIOCHEMICAL CHANGES EFFECTED BY D-MET

Agent

Study

Group

n

Examination interval (post noise)
1-2
3
10
14
hours 1 day days 7 days days
days

SOD

Reweska et al.
(2013)
(expressed
as activity
level relative
to control)
Samson et al.
(2008)
(expressed as
units/mg of
protein)
Samson et al.
(2008)
(expressed as
μM MDA +
hae/MG
protein)
Cheng et al.
(2008)
(expressed as
nmol MDA/mg
protein/h)
Reweska et al.
(2013)
(expressed as
activity level
relative to
control)
Samson et al.
(2008)
(expressed as
nM/min/mg
protein)

Control (no noise)
Saline
100 mg/kg D-Met
200 mg/kg D-Met
400 mg/kg D-Met

40
40
40
40
40

------

1.00
0.95
1.05
1.00
1.00

------

1.00
1.05
0.95
0.95
1.18**¶

------

1.00
1.10
1.05
1.05
1.18*‡

------

Control (no noise)
Saline
400 mg/kg D-Met

5
6

190
-250*

--260*

-150
230

-300*
200*

-190
--

-110
--

-190
--

Control (no noise)
Saline
400 mg/kg D-Met

5
6

12
15
--

-16
--

-12
11

-17*
11*

-13
--

-10
--

-14
--

Control (no noise)
Saline
300 mg/kg D-Met

4
4
4

0.2
0.95*
0.47*

-0.62*
0.38*

----

-0.35
0.35

----

----

----

Control (no noise)
Saline
100 mg/kg D-Met
200 mg/kg D-Met
400 mg/kg D-Met

40
40
40
40
40

------

1.00
0.95
1.20
1.30
1.20

------

1.00
3.20†‡
2.60
1.80**§
2.10**§

------

1.00
1.70
1.80
1.40
1.20

------

5
6

180
190
--

-210
--

-140
180*

-240*
180*

-230
--

-150
--

-190
--

LPO

CAT

Control (no noise)
Saline
400 mg/kg D-Met

21
days

*

p < .05
p < .01
***
p < .001
†p < .0001
‡
Significant relative to the control group
§
Significant relative to the saline group
¶
Significant relative to all other groups
**
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